Global Anthrax Vaccine Market
Global Anthrax Vaccine Market Worth Over $22 Billion by 2034, Driven by Advanced Vaccine Developments and Rising Demand for Bioterrorism Defense
11 mars 2024 13h32 HE | Research and Markets
Dublin, March 11, 2024 (GLOBE NEWSWIRE) -- The "Global Anthrax Vaccine Market by Vaccine Type, by Application, by End-User, and By Region" report has been added to ResearchAndMarkets.com's...
22157.jpg
Vaccine Research Report 2024: Global Trends, Opportunities and Competitive Analysis to 2030 Featuring GlaxoSmithKline, Merck, Pfizer, Sanofi, and CSL
11 mars 2024 11h26 HE | Research and Markets
Dublin, March 11, 2024 (GLOBE NEWSWIRE) -- The "Vaccine Market: Trends, Opportunities and Competitive Analysis [2024-2030]" report has been added to ResearchAndMarkets.com's offering.The global...
Dyadic Logo Current.jpg
CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
11 mars 2024 09h57 HE | Dyadic International, Inc.
In a release issued under the same headline on Monday, March 11th by Dyadic International, Inc. (NASDAQ: DYAI), please note that the city in the dateline should be JUPITER, Fla. not JUNIPER, Fla. The...
Dyadic Logo Current.jpg
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
11 mars 2024 08h30 HE | Dyadic International, Inc.
JUNIPER, Fla., March 11, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Global US Healthcare Advertising Market
US Healthcare Advertising Market Analysis Report 2024-2032: Increasing Presence of Generic and Me-too Drugs, Increased Consumer Reach through Mobile Advertising, Strict Rules and Regulations by FDA
08 mars 2024 06h35 HE | Research and Markets
Dublin, March 08, 2024 (GLOBE NEWSWIRE) -- The "US Healthcare Advertising Market Report by Product Type (Pharmaceuticals (Small Molecule Drugs), Biopharmaceuticals, Vaccines, Over-The-Counter (OTC)...
22157.jpg
mRNA Vaccines in the Global Infectious Diseases Market: Opportunities, Challenges, Unmet Needs, Current Companies and Market Outlook
04 mars 2024 11h54 HE | Research and Markets
Dublin, March 04, 2024 (GLOBE NEWSWIRE) -- The "mRNA Vaccines in Infectious Diseases Market Overview" report has been added to ResearchAndMarkets.com's offering.The report provides an assessment of...
New logo with tagline.jpg
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
04 mars 2024 08h30 HE | Vaxcyte, Inc.
-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by the End of the First Quarter of 2025, Followed by Topline Data from Booster Dose...
Global BCG Vaccines Market
Global BCG Vaccines Market Forecast Report: Compound Annual Growth Rate (CAGR) of 5.90% is Forecast Through the End of 2028
28 févr. 2024 11h10 HE | Research and Markets
Dublin, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The "BCG Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to ResearchAndMarkets.com's...
Dyadic Logo Current.jpg
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
28 févr. 2024 08h30 HE | Dyadic International, Inc.
JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company...
New logo with tagline.jpg
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
27 févr. 2024 16h01 HE | Vaxcyte, Inc.
-- VAX-31 Adult Program Phase 1/2 Study Enrollment Complete; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Completed Successful VAX-24 Phase 2 Adult...